Zymeworks Future Growth
Future criteria checks 1/6
Zymeworks is forecast to grow earnings and revenue by 3.5% and 9.5% per annum respectively. EPS is expected to grow by 12.8% per annum. Return on equity is forecast to be -38.3% in 3 years.
Key information
3.5%
Earnings growth rate
12.8%
EPS growth rate
Biotechs earnings growth | 23.2% |
Revenue growth rate | 9.5% |
Future return on equity | -38.3% |
Analyst coverage | Good |
Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Apr 18Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
Mar 05Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion
Feb 06Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind
Jan 31Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M
Nov 08Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone
Oct 26Zymeworks: A Roller Coaster Year
Jul 26Zymeworks And The Blue Falcon Elucidation
May 17Zymeworks Inc. (NYSE:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 27We Think Zymeworks (NYSE:ZYME) Can Afford To Drive Business Growth
Nov 17Zymeworks: Drop Due To Low Differentiation Against Competition
Jul 05Zymeworks: Oncology Drug Discovery Company With Major Big Pharma Deals
Dec 11Zymeworks' zanidatamab nabs Breakthrough Therapy tag for biliary tract cancer
Nov 30Zymeworks' zanidatamab an Orphan Drug in Europe for gastric cancer
Nov 19Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 141 | -47 | N/A | -61 | 5 |
12/31/2025 | 112 | -44 | -97 | -75 | 7 |
12/31/2024 | 89 | -65 | -73 | -33 | 8 |
12/31/2023 | 76 | -119 | -122 | -118 | N/A |
9/30/2023 | 462 | 205 | 192 | 195 | N/A |
6/30/2023 | 448 | 186 | 159 | 165 | N/A |
3/31/2023 | 446 | 173 | 108 | 116 | N/A |
12/31/2022 | 412 | 124 | 131 | 144 | N/A |
9/30/2022 | 30 | -224 | -252 | -234 | N/A |
6/30/2022 | 32 | -237 | -231 | -212 | N/A |
3/31/2022 | 28 | -240 | -224 | -207 | N/A |
12/31/2021 | 27 | -212 | -206 | -192 | N/A |
9/30/2021 | 22 | -211 | -199 | -190 | N/A |
6/30/2021 | 21 | -223 | -161 | -155 | N/A |
3/31/2021 | 31 | -194 | -161 | -155 | N/A |
12/31/2020 | 39 | -181 | -158 | -151 | N/A |
9/30/2020 | 25 | -215 | -147 | -140 | N/A |
6/30/2020 | 30 | -173 | -150 | -135 | N/A |
3/31/2020 | 26 | -163 | -113 | -98 | N/A |
12/31/2019 | 30 | -145 | -96 | -82 | N/A |
9/30/2019 | 57 | -64 | -7 | 5 | N/A |
6/30/2019 | 51 | -52 | -2 | 3 | N/A |
3/31/2019 | 65 | -29 | 17 | 20 | N/A |
12/31/2018 | 53 | -37 | 21 | 24 | N/A |
9/30/2018 | 74 | -13 | 10 | 13 | N/A |
6/30/2018 | 72 | -11 | 12 | 14 | N/A |
3/31/2018 | 52 | -16 | -7 | -5 | N/A |
12/31/2017 | 52 | -11 | -3 | 0 | N/A |
9/30/2017 | 4 | -55 | N/A | -47 | N/A |
6/30/2017 | 6 | -51 | N/A | -50 | N/A |
3/31/2017 | 11 | -47 | N/A | -41 | N/A |
12/31/2016 | 11 | -34 | N/A | -35 | N/A |
9/30/2016 | 10 | -30 | N/A | -32 | N/A |
12/31/2015 | 10 | -19 | N/A | -22 | N/A |
12/31/2014 | 2 | -13 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZYME is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ZYME is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ZYME is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ZYME's revenue (9.5% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: ZYME's revenue (9.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ZYME is forecast to be unprofitable in 3 years.